Chapter 6: Concepts of Genetics and Genomics

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today, we are digging into source material that's, well, it's right at that intersection of really complex science and absolutely critical patient care.

We're talking about the essential concepts of genetics and genomics, but tailored specifically for medical surgical nursing.

Yeah, and it's important to stress this isn't just pure biology for the lab anymore.

Our sources are really clear that this knowledge is now fundamental, absolutely key to precision health and delivering that high quality patient -centered care we're always aiming for.

Okay, so what's our mission then for this Deep Dive?

Our mission today is really give you a kind of clinical shortcut.

We want to unpack this pretty dense topic by focusing on the so what for you, the bedside nurse.

Okay.

We'll look at how these sometimes subtle DNA variations can affect a patient's health risk, how they inform management strategies, and maybe most importantly, how they define your critical role in coordinating care and advocating for your patients.

Right, and we probably need to start with some core definitions because honestly these terms are thrown around a lot, sometimes interchangeably.

They do.

The sources emphasize this priority concept that governs basically everything we'll discuss, cellular regulation.

Can you break that down?

What is it?

So cellular regulation is, it's a whole process really.

The genetic and physiological processes that control how cells grow, how they divide, how they function,

all to maintain homeostasis, that internal balance.

And if those genetic instructions get damaged?

Well then fails, and that's often where disease starts.

Okay,

which brings us then to the two big G words,

genetics and genomics.

Right, genetics.

That's the more traditional study.

Looks at single gene traits, basic heredity, you know, the mechanics of how traits pass from parent to child, Mendelian stuff.

But you said our focus is cellular regulation, complex conditions like cancer, diabetes.

So why differentiate?

What's the practical difference for a nurse?

It's really about scale and complexity.

Genomics is much broader.

It looks at the function of all of our human DNA.

All of it.

Yes, the whole network.

That includes those huge regions that don't actually code for proteins but still regulate things.

It's about how this entire system impacts cellular regulation.

So genetics is like one instruction.

Exactly.

While genomics is like trying to understand the entire, say, 20 ,000 gene operating manual and how things like environment interact with it, it's a bigger picture.

Okay, let's unpack that manual then, starting with the basic, the structure.

Okay, the basic instruction unit is the gene,

that specific segment of DNA holding the recipe for usually one protein involved in cellular regulation.

And all those genes together.

That's the genome, the full set.

Humans have somewhere between 20 ,000 and 25 ,000 genes.

And the key is how these genes are used, right?

Gene expression.

Precisely.

Gene expression is that process of selective activation, turning on a gene to make its specific protein but only when and where it's needed.

Like the insulin example the sources used.

Perfect example.

Every single cell in your body technically has the gene for insulin, but it's only activated, only expressed to actually make insulin in the beta cells of the pancreas.

That makes sense.

Selective control.

Critical for homeostasis.

And when cells get ready to divide, all that DNA gets packaged up super tightly.

Into chromosomes, those dense structures.

Humans have 23 pairs, or 46 individual chromosomes.

This packaging is crucial to make sure the genetic information gets delivered accurately to the new daughter cells.

And if we need to look at those chromosomes?

For large scale issues, yes.

We use a karyotype.

It's basically an organized picture of all 46 chromosomes taken during mitosis.

Okay.

If a cell has the correct number, 46.

We call it euploid.

If the karyotype shows something's wrong, like a missing or an extra chromosome think down syndrome, trisomy 21, that's called aneuploidy.

But you said large scale issues.

What's the limitation there?

If a karyotype only spots big missing pieces or extra ones, what about smaller changes that still cause problems?

Ah, exactly.

That's where we get into the finer points of variation within the DNA sequence itself.

A difference from the most common sequence, what we call the wild type, can be one of two key things you'll likely see noted in patient information.

First is a polymorphism.

Polymorphism.

What does that mean functionally?

It's a change in the DNA base sequence, but the protein can still be made.

The differences in how well it works or maybe how quickly it works, these are actually quite common in the population.

So if I see polymorphism on a chart, sometimes called an SMP, right, like SNP?

Yes, SMP, single nucleotide polymorphism.

That means there are differences in how that resulting protein functions.

It might be faster, slower, slightly different, but it still functions to some degree.

But if I see the word mutation,

that sounds more serious.

It generally is.

That's the really key distinction for you as a nurse.

A mutation is a DNA base sequence change that causes a significant loss of protein function.

It does function.

Yes, which often leads directly to impaired cellular regulation and frequently to disease.

So polymorphism means differences in function.

Mutation often means loss of function.

That's a critical difference.

Okay, that's clear.

Now, moving from the building blocks,

how do these variations actually get passed down?

This brings us to alleles, right?

Right.

Alleles are just the different forms or variations of a specific gene.

And we need to distinguish between the actual genetic code someone inherits.

That's the genotype, like maybe having the alleles for AO blood type.

Versus the trait we actually see.

Exactly.

The observable trait, like having type B blood, is the phenotype.

Genotype is the blueprint, phenotype is the result.

And tracking these traits, this is where that nursing assessment tool comes in.

Yes.

The sources are very clear.

The nurse is responsible for constructing the three generation pedigree, or as the source wisely suggests, we call it with patients, the family tree.

Because drawing that out helps us spot the patterns of inheritance.

Right.

Let's focus on the big three patterns mentioned.

First, autosomal dominant AD.

AD traits are often striking because they tend to appear in every generation.

Males and females are affected equally.

And the risk?

The risk for an affected parent to pass that trait to a child is always 50 % with each pregnancy.

It's a coin toss every time.

Huntington disease is the classic, often unavoidable example.

If you inherit that dominant allele, the disease eventually manifests.

Okay.

Then there's autosomal recessive, AR.

How does that differ?

With AR, the trait can seem to skip generations.

You might see it pop up only in siblings within one generation.

And this introduces the idea of a carrier.

Exactly.

A carrier is someone who has one copy of the mutated recessive allele, but doesn't actually have the disease themselves because their other allele is normal.

They're clinically unaffected, but they can pass the mutated allele on.

Sickle cell trait is a perfect example of a carrier state for an AR disorder, sickle cell anemia.

Got it.

And the third main pattern?

Sex -linked recessive, or X -linked recessive.

These disorders are much more common in males.

Why is that?

Because males only have one X chromosome.

If they inherit a mutated gene on that X, there's no second X chromosome with a potentially normal copy to compensate, like females usually have.

And there's a key rule about transmission here, isn't there?

Yes.

Very important.

A father cannot pass an X -linked trait to his son because he gives his son the Y chromosome, not the X.

So he passes it to?

All of his daughters.

They get his only X chromosome, so they will all become carriers if he has a trait.

But inheritance isn't always so, I guess, black and white, even with dominant traits, right?

Not at all.

And this brings us to two really crucial concepts that add nuance to how genes are expressed.

Penetrance and expressivity.

These are vital for counseling.

Okay, let's break those down.

Penetrance.

What is that measuring?

Penetrance is really a population -level question, it asks.

If a person has the disease -associated allele, what's the probability they will actually develop the condition?

How often is the gene expressed when it's present?

You mentioned Huntington's again.

Right.

Huntington's is considered highly penetrant.

If you have the allele, your risk of developing the disease is essentially 99 .99%.

It's almost certain.

But that's not always the case.

No.

Take the BRCA2 gene mutation associated with breast and ovarian cancer.

It has reduced penetrance.

Inheriting that mutation doesn't mean 100 % chance of cancer.

The risk is high, maybe 60 % to 80 % for breast cancer over a lifetime, but it's not guaranteed.

Knowing it's reduced is important for patient understanding and decision -making.

Okay, so penetrance is if it's expressed.

What about expressivity?

Expressivity is more personal.

It's about the degree or severity of expression when the gene is present and does cause the condition.

So same gene, different outcomes.

Potentially, yes.

The source used Neurofibromatosis Type 1 NF1.

It's an AD disorder.

You can have two people with the exact same NF1 mutation, yet one person might only have a few light brown skin markings, those cafe au lait spots, while the other develops hundreds, even thousands, of tumors all over their body.

Same mutation, but wildly different severity, different expressivity.

That difference is absolutely critical when talking to patients about what a genetic diagnosis might mean for them.

Wow, okay.

That variability is huge.

It is.

And this complexity naturally leads us to thinking about factors outside the basic DNA sequence that still have a profound impact on cellular regulation.

Right.

This is where, for me, it gets really interesting.

Beyond the inherited code itself, the source has brought up epigenetics.

The idea here is changes in gene expression without changing the underlying DNA sequence.

Mechanisms like DNA methylation.

Does that mean essentially the environment could like switch off a bad gene or switch on a good one?

In simple terms, yes, that's the concept.

Epigenetic mechanisms, DNA methylation, histone modification.

They act almost like dimmer switches or even on -off switches for genes.

They change the structures around the DNA, making a gene harder or easier to access for transcription, for being read, so they can effectively silence a gene or enhance its expression.

And yes, environmental factors, diet, toxins, stress, are thought to influence these epigenetic marks.

So they could potentially silence a normal protective gene, increasing cancer risk.

Or maybe theoretically be harnessed to help silence a mutated gene.

It's a huge area of research.

And then there's the microbiome.

This concept is just fascinating.

The genomes of all the microbes living in and on us.

Yeah, the scale is kind of mind -blowing.

The sources state that the number of microbial genomes in our body actually outnumbers our own human cell genomes by about 10 to 1.

10 to 1.

And this collective microbiome isn't just passively sitting there.

It actively influences our cellular regulation.

It can affect disease severity, even how we respond to drugs.

Is there an example of that?

The type 2 diabetes example in the text was compelling.

Researchers essentially show that altering the gut microbiome in obese men with insulin resistance actually helped reduce that resistance.

It shows a direct link between these non -human genomes and our own metabolic homeostasis.

Which ties right back into bedside care when we talk about pharmacogenomics.

Absolutely.

Pharmacogenomics is all about connecting a person's individual genetic variations to how they respond to medications.

We talked about the big family of liver enzymes, the cytochrome P450s, or CYP enzymes.

Yes, involved in metabolizing lots of drugs.

And they have a ton of common variations, those SNPs or polymorphisms we discussed.

Understanding these is critical for patient safety.

Like the warfarin example.

A common SNP in the CYP2C9 gene slows down how quickly the body metabolizes warfarin, the blood thinner.

If a patient has this variation, the drug hangs around longer, builds up.

Meaning they need a lower dose.

Much lower.

Otherwise, they're at extremely high risk for serious, potentially fatal bleeding.

Knowing their CYP2C9 status can literally be life -saving.

And the opposite can happen too, right?

With codeine.

Right.

Codeine itself is actually inactive.

It's a prodrug.

It needs the CYP2D6 enzyme to convert it into morphine, the active pain reliever.

So if someone has a variation where their CYP2D6 enzyme doesn't work well?

They get little to no pain relief from codeine.

It just doesn't get activated.

Giving them codeine is essentially pointless, maybe even harmful if it delays getting them effective pain control.

And the sources mentioned a cultural consideration here too.

Yes, a really important point about competence.

Many adults of Ethiopian heritage have a CYP2D6 variation that makes them ultra metabolizers.

Meaning?

Meaning they process certain drugs like the blood pressure medication, metoprolol, extremely quickly.

So quickly, in fact, that the drug might get eliminated before it ever reaches a therapeutic level in their blood.

So the standard dose might just not work for them?

Correct.

Their genetic makeup directly influences the choice of drug or maybe the required dosage.

It's a clear example of why this knowledge matters in practice.

This really underscores the importance and the complexity of genetic testing, which brings us right to the patient side,

the uses, and importantly,

the ethical implications.

Yeah, the sources laid out several purposes for testing, often referencing table 6 .3.

You've got carrier testing, like for prospective parents checking for recessive disorders.

Okay.

Diagnostic testing to confirm a diagnosis when someone already has symptoms.

And then predisposition testing, this is a big one.

Identifying if someone has a significantly higher risk for developing a condition before any symptoms appear, like with mutations linked to a hereditary colon cancer or breast cancer.

And the main benefit there is?

Early warning.

Identifying that high risk allows for potentially life -saving interventions like much earlier or more frequent screening or even preventative measures.

But there are significant risks too, psychological ones especially.

Huge risks.

The results are permanent, they don't change.

Learning you have a high risk for a serious condition, especially one without a cure like Huntington's, can cause immense anxiety, depression, survivor guilt, family tension.

And discrimination fears, even with legal protection.

Yes.

While GINA, the Genetic Information Nondiscrimination Act, offers vital protection against misuse of genetic information in health insurance and employment in the US,

concerns remain.

GINA doesn't cover things like life insurance, disability, or long -term care insurance.

And there's always the background worry about future loopholes or changes in law.

Patients are often very aware of these potential downstream consequences.

And this landscape gets even more complicated with the rise of direct -to -consumer genetic testing, DTC -GT.

Oh, absolutely.

These tests are marketed directly to the public, often bypassing healthcare professionals entirely, which raises several major red flags for nurses and the healthcare system.

What are the main concerns highlighted?

Well, first, there's the lack of healthcare provider involvement in ordering the test and, crucially, interpreting the results.

Second, there's a concern about test quality and regulation.

Some of these are lab -developed tests, or LDTs, which haven't always had the same level of FDA oversight.

The FDA has issued warnings about the potential for inaccuracies, false positives, or false negatives.

Which could lead to either unnecessary anxiety or false reassurance.

Exactly.

But perhaps the biggest issue, especially for nurses dealing with a fallout, is the inadequate counseling.

How so?

Take the example of testing for BRCA mutations, linked to breast cancer risk.

Some DTC companies might only test for a few of the most common mutations in these large genes.

So if you don't have one of those common ones?

You might get a report saying you're negative.

But you can still have a less common but equally dangerous mutation in BRCA1 or BRCA2, or maybe a mutation in a different gene that also increases your risk.

That negative result can give a devastatingly false sense of security.

Leading someone to potentially skip necessary screenings based on their actual family history.

Which could delay diagnosis and treatment.

It's not just a technical issue.

It has real -world, potentially life -threatening consequences.

This really highlights why proper genetic counseling is so essential.

And the sources stress it's a process, not just a one -off chat.

Absolutely.

Professional ethics require it to be a process.

And the core ethical principle guiding that process is that it must be non -directive.

Meaning?

Meaning the counselor provides all the relevant information, the risks, the benefits, the limitations of testing, the potential outcomes.

But they do not tell the patient what to do.

They don't influence the patient's final decision about whether or not to get tested.

The choice has to be the patient's alone.

That sounds incredibly difficult, especially when the stakes are high.

It can be.

And it brings up other tough ethical issues.

Like the patient's right to know versus their right not to know.

And of course, confidentiality.

Genetic test results are highly sensitive medical information and cannot be shared without explicit permission.

And assessing for coercion seems critical too.

Making sure the patient isn't being pressured by family or even by healthcare professionals into testing.

Definitely.

The sources gave that difficult example.

A patient tests positive for a mutation causing autosomal dominant HNPCC, a high risk for colon cancer.

They understand the implications, but choose not to tell their adult children.

Wow.

That denies the children the chance for potentially life -saving early screening.

It does.

But ethically, the nurse and the counselor must respect the patient's decision and their confidentiality, even when the potential consequences for family members are, frankly, heartbreaking.

It's a real ethical tightrope.

So shifting to direct nursing practice, given all this complexity, what's the medical surgical nurse's primary role?

You're often the key coordinator, the first line of assessment.

A huge part of your role is identifying those red flags that suggest a patient might have an underlying genetic risk and could benefit from a referral to genetic specialists.

What are some of those red flags?

Things like a disease occurring at an unusually early age compared to the general population, or seeing a rare disease present in two or more close family members, or finding more than one type of cancer in the same adult.

These are cues that something beyond random chance might be going on.

And that initial assessment involves constructing the?

Three -generation family tree, or pedigree.

This is listed as a required assessment tool.

It helps visualize those patterns we talked about earlier.

Beyond just assessment, what are the key nursing competencies from the sources, like from Table 6 .1?

Communication is huge.

Making sure information is clear, using plain language, maybe asking patients to explain things back in their own words to check understanding, and also correcting common myths or misinformation about genetics.

And advocacy and support.

Absolutely central.

Supporting the patient's decisions, whatever they may be, about testing, about sharing results, and being really attuned to their psychosocial needs, assessing their coping mechanisms.

People can experience significant distress, anger, guilt, depression, even if they get a good or negative test result, maybe survivor gold, if other family members tested positive.

The nursing role also extends to teaching practical strategies, right?

Risk reduction.

Yes.

If a patient is identified as having a high genetic risk, part of nursing management is teaching them about ways to mitigate that risk.

That could be environmental modification, like someone with the Alpha -1 antitrypsin deficiency gene mutation,

which predisposes to emphysema, absolutely must avoid tobacco smoke.

Or it could be more drastic.

It could involve discussing options like heightened surveillance or even preventative surgeries, like prophylactic mastectomies for women with high -risk BRCA mutations.

The nurse ensures the patient understands all their options.

And looking ahead, the sources touched on the future with gene therapy.

Right, this is still largely experimental, but it's the idea of actually trying to fix the problem at the genetic level, replacing a defective gene, inactivating it, or introducing a new healthy gene.

They mentioned an FDA -approved example.

Luxterna.

For a specific type of inherited retinal dystrophy that causes blindness,

it's a one -time injection.

But the cost cited was around $850 ,000.

So it shows both the incredible potential and the significant economic challenges.

But there's excitement around newer technologies.

Definitely.

The CRISPR -Cas9 system was mentioned.

This is a much more precise tool for gene editing.

It has the potential to overcome many of the historical hurdles gene therapy faced regarding efficiency and accuracy.

It really represents a potential leap towards actually curing some single -gene disorders, moving beyond just managing symptoms.

So, wrapping this all up, what are the absolute essential takeaways for the nurses listening?

Okay, number one.

The priority concept driving all this is cellular regulation.

Understanding how genes control cell function is key.

Number two.

Nurses must use this growing knowledge of genetics and genomics.

Use it to identify patients at risk, to advocate for ethical patient choices, especially around testing and confidentiality.

And to coordinate care.

And coordinate care effectively with genetic specialists when needed.

You're the linchpin in many cases.

And I think a final thought is that understanding the genotype, the inherited DNA, is really just the starting point, isn't it?

Absolutely.

As we saw with epigenetics and the microbiome, the environment, lifestyle, our entire biological context, it's all constantly interacting with that inherited recipe.

It's a dynamic interplay.

A really critical field and definitely one that's only going to become more important in nursing.

No question about it.

It's central to where healthcare is headed.

Thank you for joining us for this deep dive into the

really foundational role of genetics in medical surgical nursing today.

Yes.

Thank you for tuning in and engaging with these complex but vital concepts.

We genuinely hope this knowledge helps empower your practice every day.